Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11394)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2015 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm |
| Number | Citing Articles |
| 1 |
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opinion on Pharmacotherapy 2016; 17(16): 2191 doi: 10.1080/14656566.2016.1236916
|
| 2 |
Georgios K Dimitriadis, Martin O Weickert, Harpal S Randeva, Gregory Kaltsas, Ashley Grossman. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 2016; 23(9): R423 doi: 10.1530/ERC-16-0200
|
| 3 |
Burcin Özdirik, Frank Tacke, Fabian Benz, Holger Amthauer, Uli Fehrenbach, Christoph Roderburg, Henning Jann. A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. Medicine 2020; 99(25): e20820 doi: 10.1097/MD.0000000000020820
|
| 4 |
Francesco Panzuto, Maria Rinzivillo. Neuroendocrine Neoplasia Management. 2021; : 201 doi: 10.1007/978-3-030-72830-4_15
|
| 5 |
Fang Yu, Tingting Zhang, Fenghua Fu, Aiping Wang, Xinyong Liu. Preparation of Long-Acting Somatostatin and GnRH Analogues and
Their Applications in Tumor Therapy. Current Drug Delivery 2022; 19(1): 5 doi: 10.2174/1567201819666211224113311
|
| 6 |
I. A. Ilovayskaya. Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy. Meditsinskiy sovet = Medical Council 2022; (10): 148 doi: 10.21518/2079-701X-2022-16-10-148-152
|
| 7 |
Chan Shen, Ying Xu, Arvind Dasari, Ya-Chen Tina Shih, James C. Yao. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. The Oncologist 2016; 21(3): 308 doi: 10.1634/theoncologist.2015-0381
|
| 8 |
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter. From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic Advances in Medical Oncology 2024; 16 doi: 10.1177/17588359241240316
|
| 9 |
Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Waldemar Kapusta, Wawrzyniec Żmudzki, Adrianna Mróz, Beata Kos-Kudła, Grzegorz Kamiński. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center. Cancers 2023; 15(22): 5466 doi: 10.3390/cancers15225466
|
| 10 |
A. Faggiano. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story. Journal of Endocrinological Investigation 2023; 47(1): 35 doi: 10.1007/s40618-023-02170-9
|
| 11 |
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Richard A Hubner, Juan W Valle. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy 2016; 17(18): 2487 doi: 10.1080/14656566.2016.1254191
|
| 12 |
Wouter W. de Herder, Johannes Hofland. Reference Module in Biomedical Sciences. 2024; doi: 10.1016/B978-0-443-13825-6.00085-6
|
| 13 |
A. Faggiano, F. Lo Calzo, G. Pizza, R. Modica, A. Colao. The safety of available treatments options for neuroendocrine tumors. Expert Opinion on Drug Safety 2017; 16(10): 1149 doi: 10.1080/14740338.2017.1354984
|
| 14 |
Andreas F. B. Räder, Michael Weinmüller, Florian Reichart, Adi Schumacher‐Klinger, Shira Merzbach, Chaim Gilon, Amnon Hoffman, Horst Kessler. Orally Active Peptides: Is There a Magic Bullet?. Angewandte Chemie International Edition 2018; 57(44): 14414 doi: 10.1002/anie.201807298
|
| 15 |
Johannes Hofland, Aura D Herrera-Martínez, Wouter T Zandee, Wouter W de Herder. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocrine-Related Cancer 2019; 26(3): R145 doi: 10.1530/ERC-18-0495
|
| 16 |
Sally C. Lau, Omar Abdel-Rahman, Winson Y. Cheung. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Medical Oncology 2018; 35(9) doi: 10.1007/s12032-018-1189-1
|
| 17 |
Thomas Y. Wong, Kevin S. Zhang, Ripal T. Gandhi, Zachary S. Collins, Ryan O’Hara, Eric A. Wang, Kirubahara Vaheesan, Lea Matsuoka, Daniel Y. Sze, Andrew S. Kennedy, Daniel B. Brown. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09302-z
|
| 18 |
Mohammed Dawod, Teresa Alonso Gordoa, Mauro Cives, Louis De Mestier, Joakim Crona, Francesca Spada, Kjel Oberg, Marianne Pavel, Angela Lamarca. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Current Treatment Options in Oncology 2021; 22(8) doi: 10.1007/s11864-021-00863-y
|
| 19 |
Venkata K. Pokuri, Mei Ka Fong, Renuka Iyer. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Current Oncology Reports 2016; 18(1) doi: 10.1007/s11912-015-0492-7
|
| 20 |
Elettra Merola, Francesco Panzuto, Gianfranco Delle Fave. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget 2017; 8(28): 46624 doi: 10.18632/oncotarget.16686
|
| 21 |
Giandomenico Roviello, Laura Zanotti, Sergio Venturini, Alberto Bottini, Daniele Generali. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biology & Therapy 2016; 17(9): 883 doi: 10.1080/15384047.2016.1210735
|
| 22 |
Ludovica Magi, Maria Rinzivillo, Francesco Panzuto. What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterology Insights 2022; 13(1): 127 doi: 10.3390/gastroent13010014
|
| 23 |
Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Dorota Brodowska-Kania, Beata Dmochowska, Adrianna Mróz, Beata Kos-Kudła, Grzegorz Kamiński. Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study. Cancers 2024; 16(20): 3509 doi: 10.3390/cancers16203509
|
| 24 |
Fernando J. Ferrer‐Gago, Li Quan Koh. Methods and Approaches for the Solid‐Phase Synthesis of Peptide Alcohols. ChemPlusChem 2020; 85(4): 641 doi: 10.1002/cplu.201900749
|
| 25 |
Andreas F. B. Räder, Michael Weinmüller, Florian Reichart, Adi Schumacher‐Klinger, Shira Merzbach, Chaim Gilon, Amnon Hoffman, Horst Kessler. Oral aktive Peptide: Gibt es ein Patentrezept?. Angewandte Chemie 2018; 130(44): 14614 doi: 10.1002/ange.201807298
|
| 26 |
Sara Massironi, Dario Conte, Roberta Elisa Rossi. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scandinavian Journal of Gastroenterology 2016; 51(5): 513 doi: 10.3109/00365521.2015.1115117
|
| 27 |
Pamela Ryan, Alexandria Phan, Daphne Adelman, Michiko Iwasaki. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. Clinical Journal of Oncology Nursing 2016; 20(6): E139 doi: 10.1188/16.CJON.E139-E146
|
| 28 |
А. М. Тyshchenko, R. M. Smachylo, E. V. Mushenko, O. V. Ivanenko. Carcinoid of small intestine - the cause of gastro-intestinal hemorrhage and acute ileus. Klinicheskaia khirurgiia 2021; 88(5-6): 94 doi: 10.26779/2522-1396.2021.5-6.94
|
| 29 |
Antongiulio Faggiano, Anna Chiara Carratù, Elia Guadagno, Salvatore Tafuto, Fabiana Tatangelo, Ferdinando Riccardi, Carmela Mocerino, Giovannella Palmieri, Vincenzo Damiano, Roberta Siciliano, Silvana Leo, Annamaria Mauro, Lucia Franca Tozzi, Claudia Battista, Gaetano De Rosa, Annamaria Colao. Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 2016; 7(5): 5538 doi: 10.18632/oncotarget.6686
|
| 30 |
Lynn Huynh, Todor Totev, Francis Vekeman, Maureen P. Neary, Mei S. Duh, Al B. Benson. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics 2017; 20(9): 945 doi: 10.1080/13696998.2017.1337019
|
| 31 |
David L. Chan, Diego Ferone, Manuela Albertelli, Nick Pavlakis, Eva Segelov, Simron Singh. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine 2017; 57(3): 366 doi: 10.1007/s12020-017-1360-z
|
| 32 |
Rachel P. Riechelmann, Allan A. Pereira, Juliana F. M. Rego, Frederico P. Costa. Refractory carcinoid syndrome: a review of treatment options. Therapeutic Advances in Medical Oncology 2017; 9(2): 127 doi: 10.1177/1758834016675803
|
| 33 |
Francesca Spada, Roberta E. Rossi, Elda Kara, Alice Laffi, Sara Massironi, Manila Rubino, Franco Grimaldi, Sherrie Bhoori, Nicola Fazio. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals 2021; 14(6): 539 doi: 10.3390/ph14060539
|
| 34 |
Krystallenia I. Alexandraki, Anna Angelousi, Eleftherios Chatzellis, Alexandra Chrisoulidou, Nikolaos Kalogeris, Georgios Kanakis, Christos Savvidis, Dimitra Vassiliadi, Ariadni Spyroglou, Georgios Kostopoulos, Vyron Markussis, Konstantinos Toulis, Stylianos Tsagarakis, Gregory A. Kaltsas. The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine 2023; 13(2): 304 doi: 10.3390/jpm13020304
|
| 35 |
Lowell B. Anthony, Garima Gupta, Aman Chauhan. Neuroendocrine Tumours. 2024; : 363 doi: 10.1007/978-3-031-56968-5_20
|
| 36 |
Amir Mehrvarz Sarshekeh, Daniel M Halperin, Arvind Dasari. Update on Management of Midgut Neuroendocrine Tumors. International Journal of Endocrine Oncology 2016; 3(2): 175 doi: 10.2217/ije-2015-0004
|
| 37 |
Luohai Chen, Nuerailaguli Jumai, Qiao He, Man Liu, Yuan Lin, Yanji Luo, Yu Wang, Min-hu Chen, Zhirong Zeng, Xiangsong Zhang, Ning Zhang. The role of quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis. European Journal of Nuclear Medicine and Molecular Imaging 2023; 50(2): 525 doi: 10.1007/s00259-022-05971-x
|
| 38 |
Christoph J Auernhammer, Christine Spitzweg, Martin K Angele, Stefan Boeck, Ashley Grossman, Svenja Nölting, Harun Ilhan, Thomas Knösel, Julia Mayerle, Martin Reincke, Peter Bartenstein. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. The Lancet Diabetes & Endocrinology 2018; 6(5): 404 doi: 10.1016/S2213-8587(17)30401-1
|
| 39 |
Jorge Enrique Machado-Alba, Manuel Enrique Machado-Duque. Prescription patterns of long-acting somatostatin analogues. SAGE Open Medicine 2017; 5 doi: 10.1177/2050312117694795
|
| 40 |
Colin Bacorn, Esther Kim, Alexander D Borowsky, Lily Koo Lin. Previously undiagnosed neuroendocrine tumour mimicking breast cancer metastasis to the orbit. BMJ Case Reports 2020; 13(5): e234629 doi: 10.1136/bcr-2020-234629
|
| 41 |
Yuhong Wang, Wei Wang, Kaizhou Jin, Cheng Fang, Yuan Lin, Ling Xue, Shiting Feng, Zhiwei Zhou, Chenghao Shao, Minhu Chen, Xianjun Yu, Jie Chen. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncology Letters 2017; 13(3): 1165 doi: 10.3892/ol.2017.5591
|
| 42 |
M. Pavel, K. Öberg, M. Falconi, E.P. Krenning, A. Sundin, A. Perren, A. Berruti. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2020; 31(7): 844 doi: 10.1016/j.annonc.2020.03.304
|
| 43 |
M. Albertelli, E. Nazzari, S. Sciallero, F. Grillo, S. Morbelli, F. De Cian, G. Cittadini, E. Ambrosetti, A. Ciarmiello, D. Ferone. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation 2017; 40(11): 1265 doi: 10.1007/s40618-017-0692-0
|
| 44 |
Anjie Yang, Jocelyn Brown, Ernie Mak. Persistent Diarrhea after Celiac Plexus Block in a Pancreatic Cancer Patient: Case Report and Literature Review. Journal of Palliative Medicine 2016; 19(1): 83 doi: 10.1089/jpm.2015.0117
|
| 45 |
Chandrikha Chandrasekharan. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America 2020; 29(2): 293 doi: 10.1016/j.soc.2019.11.004
|
| 46 |
Amanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, Jonas Ahlstedt, Sven-Erik Strand, Bo Åkerström. Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. Antioxidants 2021; 10(8): 1271 doi: 10.3390/antiox10081271
|
| 47 |
Stephanie M Barrows, Beilei Cai, Catherine Copley-Merriman, Kelly R Wright, Colleen V Castro, Raoudha Soufi-Mahjoubi. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World Journal of Meta-Analysis 2018; 6(2): 9-20 doi: 10.13105/wjma.v6.i2.9
|
| 48 |
Biagio Cangiano, Letizia Maria Fatti, Luca Persani, Giovanni Vitale. Nuovi farmaci a bersaglio molecolare nei tumori neuroendocrini gastroenteropancreatici. L'Endocrinologo 2017; 18(6): 280 doi: 10.1007/s40619-017-0359-2
|
| 49 |
George A. Fisher. Textbook of Gastrointestinal Oncology. 2019; : 269 doi: 10.1007/978-3-030-18890-0_16
|
| 50 |
Yichan Zhou, James Weiquan Li, Noriya Uedo. Multimodal management of foregut neuroendocrine neoplasms. Best Practice & Research Clinical Gastroenterology 2024; 68: 101889 doi: 10.1016/j.bpg.2024.101889
|
| 51 |
Nagarjun Subash, Mishel Maria Papali, Khatri Prashant Bahadur, Chaithanya Avanthika, Sharan Jhaveri, Srijani Thannir, Meet Joshi, Sai Sudha Valisekka. Recent Advances in the Diagnosis and Management of Carcinoid Syndrome. Disease-a-Month 2022; 68(7): 101304 doi: 10.1016/j.disamonth.2021.101304
|
| 52 |
Fernando J. Ferrer‐Gago, Li Quan Koh, David P. Lane. Functionalized Resins for the Synthesis of Peptide Alcohols. Chemistry – A European Journal 2020; 26(2): 379 doi: 10.1002/chem.201903965
|
| 53 |
Pam A T Heutinck, L Ingeborgh van den Born, Jan A M van Laar, P Martin van Hagen, Dzenita Smailhodzic, Magda A Meester-Smoor, Caroline C W Klaver, Virginie J M Verhoeven, Alberta A H J Thiadens. Somatostatin analogues as a treatment option for cystoid maculopathy in retinitis pigmentosa. BMJ Open Ophthalmology 2024; 9(1): e001722 doi: 10.1136/bmjophth-2024-001722
|
| 54 |
David Cella, Jennifer L. Beaumont, Stacie Hudgens, Florence Marteau, Marion Feuilly, Aude Houchard, Pablo Lapuerta, John Ramage, Marianne Pavel, Dieter Hörsch, Matthew H. Kulke. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clinical Therapeutics 2018; 40(12): 2006 doi: 10.1016/j.clinthera.2018.10.008
|
| 55 |
ME Pavel, C Becerra, K Grosch, W Cheung, J Hasskarl, JC Yao. Effect of everolimus on the pharmacokinetics of octreotide long‐acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT‐2 trial. Clinical Pharmacology & Therapeutics 2017; 101(4): 462 doi: 10.1002/cpt.559
|
| 56 |
Sathish Kumar Mungamuri, Anil Kumar Pasupulati, Vijay Aditya Mavuduru. Exploring Pancreatic Metabolism and Malignancy. 2019; : 215 doi: 10.1007/978-981-32-9393-9_13
|
| 57 |
Xiang Li, Yanqing Liu, Wei Huang, Xin Xie, Hongping Zhu, Cheng Peng, Bo Han. Advancements in Small Molecule PROTACs Containing Indole/Spiro-fused Oxindole Scaffolds: An Emerging Degrader Targeting Cancers. Anti-Cancer Agents in Medicinal Chemistry 2023; 23(10): 1164 doi: 10.2174/1871520622666220509175305
|
| 58 |
Sara Pusceddu, Natalie Prinzi, Alessandra Raimondi, Francesca Corti, Roberto Buzzoni, Maria Di Bartolomeo, Ettore Seregni, Marco Maccauro, Jorgelina Coppa, Massimo Milione, Vincenzo Mazzaferro, Filippo de Braud. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori Journal 2019; 105(2): 113 doi: 10.1177/0300891618765362
|
| 59 |
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, Mark Kidd, Sebastian Krug, Rita Lawlor, Ilaria Marinoni, Aurel Perren, Aldo Scarpa, Halfdan Sorbye, Marianne Ellen Pavel, Matthias M Weber, Irvin Modlin, Thomas M Gress. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. Gut 2021; 70(9): 1768 doi: 10.1136/gutjnl-2020-321300
|
| 60 |
Yue Cheng, Lowell Anthony, Chris Delcher, Daniela C Moga, Aman Chauhan, Bin Huang, Val Adams. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors. The Oncologist 2023; 28(6): 479 doi: 10.1093/oncolo/oyad057
|
| 61 |
G. García Rayado, M.A. Simón Marco. Tumores del intestino delgado. Pólipos intestinales. Poliposis familiares. Síndrome carcinoide. Linfomas. Sarcomas intestinales. Medicine - Programa de Formación Médica Continuada Acreditado 2016; 12(4): 189 doi: 10.1016/j.med.2016.02.012
|
| 62 |
Eva Lesén, Åse Björstad, Ingela Björholt, Tom Marlow, Entela Bollano, Marion Feuilly, Florence Marteau, Staffan Welin, Anna-Karin Elf, Viktor Johanson. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scandinavian Journal of Gastroenterology 2018; 53(12): 1509 doi: 10.1080/00365521.2018.1531653
|
| 63 |
Norberto Perico, Piero Ruggenenti, Annalisa Perna, Anna Caroli, Matias Trillini, Sandro Sironi, Antonio Pisani, Eleonora Riccio, Massimo Imbriaco, Mauro Dugo, Giovanni Morana, Antonio Granata, Michele Figuera, Flavio Gaspari, Fabiola Carrara, Nadia Rubis, Alessandro Villa, Sara Gamba, Silvia Prandini, Monica Cortinovis, Andrea Remuzzi, Giuseppe Remuzzi, Maarten W. Taal. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLOS Medicine 2019; 16(4): e1002777 doi: 10.1371/journal.pmed.1002777
|
| 64 |
Jaume Capdevila, Enrique Grande, Rocío García-Carbonero, Marc Simó, Mª Isabel del Olmo-García, Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, Virginia Pubul. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. The Oncologist 2022; 27(4): e328 doi: 10.1093/oncolo/oyab041
|
| 65 |
Kavisha R. Ulapane, Brian M. Kopec, Mario E. G. Moral, Teruna J. Siahaan. Peptides and Peptide-based Biomaterials and their Biomedical Applications. Advances in Experimental Medicine and Biology 2017; 1030: 167 doi: 10.1007/978-3-319-66095-0_8
|
| 66 |
Luohai Chen, Jie Chen. Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. Journal of Pancreatology 2019; 2(3): 91 doi: 10.1097/JP9.0000000000000023
|
| 67 |
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Carcinoid-syndrome: recent advances, current status and controversies. Current Opinion in Endocrinology, Diabetes & Obesity 2018; 25(1): 22 doi: 10.1097/MED.0000000000000376
|